The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis.
Ippazio Cosimo AntonazzoPaolo Angelo CortesiGerardo Miceli SopoGiampiero MazzagliaPierFranco ConteLorenzo Giovanni MantovaniPublished in: Cancers (2023)
This study estimated the appropriate price for tucatinib according to different WTP in order to help healthcare decision makers to better understand the treatment value.